FEDORA: A phase II study to evaluate the safety, toxicity and tolerability of the combination of fedratinib and ropeginterferon alfa-2b, in patients with myelofibrosis

Project Details

Short titleFEDORA: A phase II study to evaluate the safety, toxicity and tolerability of the combination of fedratinib and ropeginterferon alfa-2b, in patients with myelofibrosis
StatusActive
Effective start/end date31/12/2130/06/26

Funding

  • AOP Orphan Pharmaceuticals GmbH